GSK’s antibody-drug conjugate strategy may be making more headlines recently, but the British pharma hasn’t forgotten about ...
Chronic obstructive pulmonary disease (COPD) makes it hard to breathe. Narrowed airways can make you cough, wheeze, and feel short of breath. It can affect how you exercise, work, and do other daily ...
An anti-inflammation injectable drug called dupilumab can reduce mucus buildup and improve breathing among asthma patients, a ...
New findings from the ERS Global Congress on Lung Diseases present a paradigm shift in COPD treatment: Early identification of type 2 inflammation and personalized biologic therapy.
GSK is shelling out $85 million up front, and possibly $745 million overall, for an RNA-based therapy it sees helping a ...
-Ritedose is the development partner and manufacturer of Ohtuvayre (ensifentrine)*, the first inhaled product with a novel mechanism of action in more than 20 years for the maintenance treatment of ...
Every 30 seconds, someone in the world will experience a flare-up of their asthma or chronic obstructive pulmonary disease (COPD) symptoms. For decades, the standard treatment for these potentially ...
Regeneron and Sanofi shares edged higher Friday after their drug to treat chronic obstructive pulmonary disease (COPD) received approval from the Food and Drug Administration (FDA). The drug, Dupixent ...
Quit smoking and control your indoor air quality. Exposure to smoke, dust, fumes, vapors and chemicals can worsen your COPD.
Recent medical research reveals promising developments in the treatment of patients suffering from both diabetes and chronic obstructive pulmonary disease. The study, involving nearly 394,000 adults, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback